Navigation Links
Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
Date:3/31/2009

VIENNA, March 31 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that it will host a conference call today to discuss the U.S. Food and Drug Administration's (FDA) approval of IXIARO(R), a new vaccine for the prevention of Japanese Encephalitis (JE). The initial target for use of Intercell's vaccine - the only such product currently manufactured for the U.S. market - will be adult travelers and military personnel who visit or are deployed to affected countries, including India, China, and other parts of Asia.

    Conference Call Details

    Time: 3 p.m. CET, 2 p.m. GMT and 9 a.m. EDT.

    Chairpersons: Gerd Zettlmeissl (CEO) and Thomas Lingelbach (COO and
    Managing Director Intercell Biomedical Ltd., Scotland)

    Dial-In:
    Austria: +43 (0)2682 205 62 92
    Germany: +49 (0)69 589 990 507
    Switzerland: +41 (0)434 56 92 61
    US: +1 334 323 62 01
    UK: +44 (0)20 7131 2799

Please quote "Intercell Call" and an operator will then put you through to the Intercell conference call.

The presentation will be made available on the Intercell website prior to the conference call.

About Japanese Encephalitis

Japanese Encephalitis is a mosquito-borne infection that strikes 30,000 to 50,000 individuals a year, causing 10,000 to 15,000 deaths (both probably an underestimate due to underreporting and other factors). Up to 50 percent of survivors have persistent neurological sequelae. Japanese Encephalitis is the leading cause of viral neurological disease and disability in Asia and the most important viral encephalitis in Asia. The disease is most common in several developing countries in Asia, including India and China. As there is no specific treatment for JE, health care experts recommend vaccination as the only highly effective protection for the millions of travelers and military personnel who live in or trav
'/>"/>

SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
2. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
3. Iomai Stockholders Approve Merger With Intercell Subsidiary
4. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
5. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
6. New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
9. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2008 Financial Results
11. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Francisco, CA (PRWEB) April 16, 2015 ... scheduled to report first quarter results on Thursday, April ... announcement, Cytokinetics’ senior management will host a conference call ... financial results and the company’s outlook for the future. ... can be accessed from the homepage and in the ...
(Date:4/16/2015)... April 16, 2015  Schulman Associates IRB, Inc., the ... signed a long-term lease on Laboratory Drive in the ... . The location will house review board and ... high quality reviews and customer service to clients. ... represented Schulman in the deal, while Capital Associates Management, ...
(Date:4/16/2015)... April 16, 2015 OncoTAb, ... Charlotte (UNC Charlotte) spin-out company, announced today the ... Ph.D., M.D., as Chief Operating Officer (COO). Cooper ... experience in developing clinical diagnostic and biotechnology platforms ... disease. , Cooper’s extensive career transcends the field ...
(Date:4/16/2015)... , April 16, 2015 /PRNewswire/ - Portage Biotech ... Canadian Securities Exchange: PBT.U), is pleased to announce that ... Show on April 25, 2015 to be held in ... Gregory Bailey and Mr. James Mellon ... and an update on the key programs at its ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4
... Six new stem cell therapies, all forecast to reach physicians ... Summit on February 16 in New York City. These new therapies ... at least one FDA-approved stem cell drug. New studies showing rehydration ... are also on the agenda. , The Stem Cell Summit is ...
... REHOVOT, Israel, December 31 D-Pharm Ltd ... its,Phase III clinical study of DP-b99 (MACSI). The first patient ... trial involves,numerous medical centers in the US, Canada, Europe, Israel, ... product developed,for protection of brain cells suffering from restricted blood ...
... ... For The Massachusetts Biotechnology Council , ... Boston, MA (PRWEB) December 31, 2009 -- Social Media ... Biotechnology Council’s (MassBio) has selected the Boston-based Social Media Marketing Agency to plan and ...
Cached Biology Technology:5th Annual Summit to Feature New Stem Cell Therapies 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 3 The Massachusetts Biotechnology Council Selects Social Media Marketing Agency 451 Marketing To Develop A Social Media Strategy For 2010 2 The Massachusetts Biotechnology Council Selects Social Media Marketing Agency 451 Marketing To Develop A Social Media Strategy For 2010 3
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, ... label any protein of their choice with any of ... cells, by introducing a single reactive artificial amino acid. ... researchers to label even rare proteins very precisely for ...
... metabolism at the University of California, San Francisco (UCSF) ... fat storage in worms, offering a new tool for ... with obesity. As described in a paper published ... the UCSF team took armies of microscopic worms ...
... transplanting adult stem cells to treat or even cure age-related ... reality. In a study published today in Stem ... the first time, the ability to create retinal cells derived ... that die and cause loss of sight. Age-related ...
Cached Biology News:UCSF team shows how to make skinny worms fat and fat worms skinny 2UCSF team shows how to make skinny worms fat and fat worms skinny 3Stem cell therapy for age-related macular degeneration -- a step closer to reality 2
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: